cabazitaxel and Optic-Atrophy

Taxanes are a group of cytotoxic anti-cancer agents used in the treatment of solid tumours. The neurotoxic adverse effects of docetaxel and paclitaxel, including optic neuropathy, are well known. Cabazitaxel is a new generation taxane showing lesser drug resistance when compared with previous ones. Optic atrophy due to the use of cabazitaxel has not been previously reported. Herein, we report a patient with prostate cancer who developed optic atrophy after cabazitaxel treatment.

Topics: Adenocarcinoma; Antineoplastic Agents; Humans; Male; Middle Aged; Optic Atrophy; Prostatic Neoplasms, Castration-Resistant; Taxoids